Hager Biosciences


Hager Bio is a drug discovery and development company focused on small-molecule therapeutics for neuropsychiatric and neurological disorders. The organization develops multi-target small-molecule candidates using a discovery platform oriented to modulate complementary CNS signaling networks, and advances assets through preclinical safety assessments, patenting, and partnering activities.

Industries

Biotechnology
Health Care
Medical
Pharmaceutical
Therapeutics
Biotechnology Research

Nr. of Employees

small (1-50)

Hager Biosciences

Bethlehem, Pennsylvania, United States


Patents

Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

US-12528819-B2

View Details

Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

US-12291535-B2

View Details

Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists

US-12275744-B2

View Details

Imidazolo derivatives, compositions and methods as orexin antagonists

US-12187738-B2

View Details

Imidazolo derivatives, compositions and methods as orexin antagonists

US-12187737-B2

View Details

Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

US-12024525-B2

View Details
View All Patents

Products

Small-molecule therapeutic candidates for substance use disorders (SUD)

Series of first-in-class small-molecule candidates designed to modulate multiple receptors implicated in craving, stress-induced relapse and insomnia.

Small-molecule therapeutic candidates for Alzheimer’s disease (AD)

Novel candidates designed to target neuromodulator circuits implicated in disrupted sleep architecture, impaired glymphatic clearance, neurodegeneration and psychotic symptoms.


Services

Engagements for collaboration, licensing and partnering to advance discovery assets and clinical development.

Support and collaboration for advancing assets toward clinical development.

Expertise Areas

  • Small-molecule drug discovery
  • Polypharmacology / multi-target therapeutic design
  • Neuroscience and neuropsychiatric therapeutics
  • Medicinal chemistry
  • Show More (4)

Key Technologies

  • Small-molecule discovery platforms
  • Polypharmacology design strategies
  • Receptor-targeted drug design
  • Medicinal chemistry optimization
  • Show More (2)

News & Updates

Announcement of multiple recently granted patents reflecting progression of discovery research and IP generation.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.